Work

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer

Year: 2014

Type: article

Source: Cancer Letters

DOI: 10.1016/j.canlet.2014.02.018

Authors: Jatin Roper, Mark J. Sinnamon, Erin M. Coffee, Peter Belmont, Lily Keung, Larissa Georgeon-Richard, Wei Vivian Wang, Anthony C. Faber, Jihye Yun, Ömer H. Yilmaz, Roderick T. Bronson, Eric S. Martin, Philip N. Tsichlis, Kenneth E. Hung

Institutions: Tufts Medical Center, Massachusetts General Hospital, Center for Systems Biology, NewYork–Presbyterian Hospital, Koch Institute for Integrative Cancer Research At MIT, Massachusetts Institute of Technology, Harvard University, Dana-Farber/Harvard Cancer Center, Pfizer (United States)

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: American Gastroenterological Association, National Institute on Aging, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases

Awards: G1207694440, G5996124202, G770305515

OpenAlex ID: W2002124262

FWCI: 2.921

Cites: 52

Cited by: 42

Related to: 10